X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (41) 41
index medicus (31) 31
oncology (31) 31
male (17) 17
adult (15) 15
clinical neurology (15) 15
glioblastoma (15) 15
temozolomide (14) 14
abstracts (13) 13
female (13) 13
middle aged (13) 13
aged (12) 12
brain neoplasms - pathology (12) 12
glioblastoma multiforme (11) 11
magnetic resonance imaging (11) 11
prognosis (11) 11
radiotherapy (11) 11
brain neoplasms - drug therapy (10) 10
brain neoplasms - therapy (10) 10
chemotherapy (10) 10
cancer (9) 9
glioblastoma - pathology (9) 9
glioblastoma - therapy (9) 9
bevacizumab (8) 8
brain neoplasms - mortality (8) 8
care and treatment (8) 8
glioblastoma - mortality (8) 8
gliomas (8) 8
models, biological (8) 8
survival analysis (8) 8
treatment outcome (8) 8
aged, 80 and over (7) 7
article (7) 7
brain (7) 7
surgery (7) 7
survival (7) 7
adjuvant temozolomide (6) 6
brain cancer (6) 6
central nervous system neoplasms - pathology (6) 6
disease-free survival (6) 6
glioblastoma - drug therapy (6) 6
glioma (6) 6
phase-ii trial (6) 6
proliferation (6) 6
radiation therapy (6) 6
research (6) 6
tumors (6) 6
angiogenesis (5) 5
brain neoplasms - radiotherapy (5) 5
clinical trials (5) 5
combined modality therapy (5) 5
dacarbazine - analogs & derivatives (5) 5
follow-up studies (5) 5
glioblastoma - diagnosis (5) 5
glioma - pathology (5) 5
high-grade gliomas (5) 5
malignant glioma (5) 5
mutation (5) 5
patients (5) 5
trial (5) 5
brain metastases (4) 4
brain neoplasms - diagnosis (4) 4
brain neoplasms - genetics (4) 4
brain tumors (4) 4
cancer therapies (4) 4
central nervous system neoplasms - therapy (4) 4
clinical trials as topic (4) 4
development and progression (4) 4
disease progression (4) 4
dosage and administration (4) 4
dose-response relationship, drug (4) 4
drug therapy (4) 4
glioblastoma - radiotherapy (4) 4
growth (4) 4
health aspects (4) 4
high-dose methotrexate (4) 4
individual patients (4) 4
kaplan-meier estimate (4) 4
neoplasm invasiveness (4) 4
neoplasm recurrence, local - drug therapy (4) 4
patient outcomes (4) 4
phase-ii (4) 4
radiation (4) 4
radiation-therapy (4) 4
recurrent malignant glioma (4) 4
risk factors (4) 4
whole-brain radiotherapy (4) 4
animals (3) 3
applied mathematics (3) 3
astrocytoma (3) 3
bevacizumab plus irinotecan (3) 3
brain - pathology (3) 3
brain neoplasms - blood supply (3) 3
brain tumor (3) 3
cancer research (3) 3
cancer treatment (3) 3
cell biology (3) 3
central nervous system neoplasms - diagnosis (3) 3
central nervous system neoplasms - drug therapy (3) 3
computer simulation (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Weller, Michael and Butowski, Nicholas and Tran, David D and Recht, Lawrence and Recht, Lawrence D and Lim, Michael and Hirte, Hal and Ashby, Lynn and Mechtler, Laszlo and Goldlust, Samuel and Goldlust, Samuel A and Iwamoto, Fabio and Drappatz, Jan and O'Rourke, James and O'Rourke, Donald M and Wong, Mark and Hamilton, Mark G and Hamilton, Mark and Finocchiaro, Gaetano and Perry, James and Wick, Wolfgang and Green, Jennifer and He, Yi and Turner, Christopher D and Yellin, Michael J and Keler, Tibor and Davis, Thomas A and Stupp, Roger and Sampson, John H and Campian, Jian and Becker, Kevin and Barnett, Gene and Nicholas, Garth and Desjardins, Annick and Benkers, Tara and Wagle, Naveed and Groves, Morris and Kesari, Santosh and Horvath, Zsolt and Merrell, Ryan and Curry, Richard and Schuster, David and Mrugala, Maciej and Jensen, Randy and Trusheim, John and Lesser, Glenn and Belanger, Karl and Sloan, Andrew and Purow, Benjamin and Fink, Karen and Raizer, Jeffrey and Schulder, Michael and Nair, Suresh and Peak, Scott and Brandes, Alba and Mohile, Nimish and Landolfi, Joseph and Olson, Jon and Jennens, Ross and DeSouza, Paul and Robinson, Bridget and Crittenden, Marka and Shih, Kent and Flowers, Alexandra and Ong, Shirley and Connelly, Jennifer and Hadjipanayis, Costas and Giglio, Pierre and Mott, Frank and Mathieu, David and Lessard, Nathalie and Sepulveda, Sanchez Juan and Lövey, József and Wheeler, Helen and Inglis, Po-Ling and Hardie, Claire and Bota, Daniela and Lesniak, Maciej and Portnow, Jana and Frankel, Bruce and Junck, Larry and Thompson, Reid and Berk, Lawrence and McGhie, John and Macdonald, David and Saran, Frank and Soffietti, Riccardo and Blumenthal, Deborah and André de, Sá Barreto Costa Marcos and Nowak, Anna and Singhal, Nimit and Hottinger, Andreas and Schmid, Andrea and Srkalovic, Gordan and Baskin, David and Fadul, Camilo and Nabors, Louis and LaRocca, Renato and Villano, John and Paleologos, Nina and ... and ACT IV Trial Investigators and ACT IV trial investigators
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet... 
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2019, Volume 21, Issue Supplement_6, pp. vi136 - vi136
Abstract BACKGROUND Molecular testing (MT) is utilized in neuro-oncology with increasing frequency. Multiple molecular panels are available providing a... 
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2018, Volume 20, Issue suppl_6, pp. vi58 - vi59
Abstract EGFR mutation status is strongly correlated with leptomeningeal carcinomatosis in non-small-cell lung cancer. Historically, patients were treated with... 
Abstracts
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, p. e79115
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e51951
Journal Article
Neurosurgical focus, 2007, Volume 23, Issue 4, p. E1
Meningiomas are extraaxial central nervous system tumors most often discovered in middle to late adult life, and are more often seen in women. Ninety percent... 
Diagnostic Imaging | Neurosurgical Procedures | Humans | Risk Factors | Meningeal Neoplasms - etiology | Meningeal Neoplasms - diagnosis | Meningioma - diagnosis | Meningioma - etiology | Meningeal Neoplasms - therapy | Meningioma - therapy
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5415 - 5415
Abstract Background: Central nervous system (CNS) lymphoma manifests as a highly aggressive non-Hodgkins lymphoma, either confined to the central nervous... 
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 09/2014, Volume 124, Issue 9, pp. 4082 - 4092
Journal Article
Neurology, ISSN 0028-3878, 07/2009, Volume 72, Issue 8, p. 773
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2019, Volume 21, Issue Supplement_6, pp. vi223 - vi223
Abstract Glioblastoma (GBM) is the most aggressive primary brain tumor with a median overall survival of 15 months with standard-of-care treatment. GBM... 
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2019, Volume 21, Issue Supplement_6, pp. vi162 - vi163
Abstract Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of only 15 months with standard of care treatment. Lacunarity, a... 
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2019, Volume 21, Issue Supplement_6, pp. vi79 - vi80
Abstract INTRODUCTION Locations of gliomas may influence clinical presentations, molecular profiles, treatment options, and prognoses. Using the Mayo Clinic... 
Journal Article
Current Oncology Reports, ISSN 1523-3790, 8/2017, Volume 19, Issue 8, pp. 1 - 8
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 3/2014, Volume 117, Issue 1, pp. 93 - 101
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2018, Volume 20, Issue suppl_6, pp. vi160 - vi160
Abstract The hallmark of glioblastoma (GBM) is poor survivorship. However, a small subset (5%) of patients live greater than 5 years (extreme survivors (ES)).... 
Abstracts
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.